在COVID-19后应对肺纤维化风险:尖端治疗方法
Sy Duong-Quy1,2,3, Cong Nguyen Hai4, Tuan Huynh-Anh5
1Biomedical Research Centre, Lam Dong Medical College, Dalat city, Vietnam.
在COVID-19之后的肺纤维化是一种严重的长期COVID并发症. 这篇评论总结了它的负担,诸如宁泰达尼布和皮尔芬尼之类的治疗方法,以及为更好的患者结果而出现的新疗法.
科学领域:
- 肺部病理学 肺部病理学
- 传染性疾病 传染性疾病
- 放射学 放射学是一门学科.
背景情况:
- 肺纤维化 (PF) 是长期COVID的一个重要并发症,特别是在严重的病例中.
- 高分辨率计算机断层扫描 (HRCT) 对于在COVID-19后的PF中诊断纤维性病变至关重要.
- 了解COVID-19后的PF对于管理长期COVID呼吸系统后果至关重要.
研究的目的:
- 审查COVID-19后的PF发病率和疾病负担.
- 概述现有和新型的治疗策略,用于PF管理.
- 评估治疗疗效,并确定COVID-19后的PF中的挑战.
主要方法:
- 系统审查方法.
- 对COVID-19后的PF现有文献的分析.
- 评估治疗干预及其结果.
主要成果:
- 在COVID-19之后的PF带来了相当大的疾病负担.
- 已建立的治疗方法包括抗纤维素药物,如宁泰达尼布和皮尔芬尼.
- 新兴疗法包括抗干细胞,干细胞和Rho-酶抑制剂.
结论:
- COVID-19 后的 PF 需要全面的管理策略.
- 新型疗法显示出前景,但需要进一步的临床验证.
- 持续的研究对于优化治疗和改善患者生活质量至关重要.
更多相关视频
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018
02:46A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
Published on: January 20, 2023
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Flail Chest-II
Assessment:
1. Clinical Evaluation:
History:
Pneumothorax-II
Clinical Manifestations:
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Cystic Fibrosis: Management
Sinus disease and chronic...
